Potential Fibrocaps royalty and milestone payments

4th June 2013

Vectura Group plc

Potential royalty and milestone payments on Fibrocaps™

Chippenham, UK - 4th June 2013: Vectura Group plc ("Vectura" or the "Company"; LSE: VEC), announces that the Company could receive a £2m change of control payment as part of the potential acquisition announced today, by The Medicines Company of ProFibrix B.V. The acquisition is subject to a satisfactory review of the pending Phase 3 clinical trial results of ProFibrix's lead biologic, Fibrocaps™, expected in Q3 2013. In addition to the change of control payment, Vectura will potentially receive payments based on certain approval and sales milestones, plus a single digit royalty on sales of Fibrocaps™.

The patents licensed by Vectura to Profibrix B.V. in relation to Fibrocaps were acquired as part of the Innovata plc acquisition. The only assets in Vectura's balance sheet at 31 March 2013 in relation to its agreements with Profibrix B.V. were £0.4m of intangible assets.

Dr Chris Blackwell, Chief Executive of Vectura commented:

"Today's announcement further demonstrates Vectura's commitment to monetise value from its extensive intellectual property portfolio."

About ProFibrix

ProFibrix (www.profibrix.com) was founded in 2004 and is headquartered in Leiden, The Netherlands, with a subsidiary in Seattle, WA, USA. The company leverages its expertise in fibrinogen technology to develop and bring to market innovative products for the hemostasis and regenerative medicine markets. Human fibrinogen plays a pivotal role in blood clotting and tissue healing. ProFibrix is led by a team with extensive commercial, clinical and scientific experience in the hemostasis field.

About Fibrocaps

Fibrocaps is a mixture of two essential blood clotting proteins, fibrinogen and thrombin, formulated as a unique dry powder topical product, which is being developed to stop bleeding during or after surgery. Fibrocaps is differentiated from existing liquid fibrin sealants and hemostats: it is ready for immediate use, is stable at room temperature and does not require frozen storage or thawing.

About the FINISH-3 trial

FINISH-3 is a prospective, randomized, Phase 3 trial of Fibrocaps in patients undergoing spinal, liver, vascular and soft tissue surgery. Patients were enrolled in the U.S. and Europe. Results of FINISH-3 are expected in the third quarter of 2013.

About The Medicines Company

The Medicines Company (www.themedco.com) provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.

Enquiries

About Vectura

Vectura Group plc and its subsidiaries is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airway diseases. This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth in excess of $30 billion worldwide.

Vectura has seven products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter, GlaxoSmithKline (GSK) and Tianjin King York Group Company Limited (KingYork).

Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. For further information, please visit Vectura's website at www.vectura.com.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is provided by RNS

The company news service from the London Stock Exchange

END